ArriVent BioPharma, Inc. (AVBP): Cash & Equivalents
$45.54M
As of 2025-12-31
$154.68M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $45.54M | -38.7% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $74.29M | -50.6% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $150.39M | n/a | 2025-03-03, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | 2025-12-31 | $45.54M | -38.7% |
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | $226.65M | +192.9% |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $77.56M | -52.6% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $287.42M | -48.7% |
| Liquidia Corp (LQDA) | 2025-12-31 | $190.68M | +8.0% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $41.32M | -18.7% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $307.53M | -34.8% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $60.18M | -43.0% |
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | $58.45M | +54.7% |
Compare AVBP, AMLX, RCKT, KROS side by side · Screen every company in Pharmaceutical Preparations ↗